Health
An Intriguing Approach to Slow Alzheimer’s Shows Mixed Results
Key Points
Supported by An Intriguing Approach to Slow Alzheimer’s Shows Mixed Results The device, a headset delivering light and sound, is based on the theory that audiovisual stimulation can evoke brainwave responses that might help preserve neurological function. The largest trial to date of a headset device that delivers flickering light and sound in an attempt to slow the progression of Alzheimer’s has delivered mixed results.
Supported by
An Intriguing Approach to Slow Alzheimer’s Shows Mixed Results
The device, a headset delivering light and sound, is based on the theory that audiovisual stimulation can evoke brainwave responses that might help preserve neurological function.
The largest trial to date of a headset device that delivers flickering light and sound in an attempt to slow the progression of Alzheimer’s has delivered mixed results.
The device is based on the theory that audiovisual stimulation can evoke brainwave responses that might help preserve neurological function and clear waste from the brain. The idea is appealing because, if such a treatment works, it could provide an accessible non-drug alternative to Alzheimer’s medications that are expensive and carry significant safety risks.
Results of the study of the device, to be presented Monday evening at a major Alzheimer’s conference, showed that the 12-month trial involving participants with mild to moderate Alzheimer’s did not achieve its primary goal. The overall group of patients who used the audiovisual device did not experience slower cognitive decline than those who used an inactive placebo device called a sham.
Patients with moderate Alzheimer’s showed no benefit at all from the system, called Spectris, according to data provided by the company, Cognito Therapeutics. But for patients with mild Alzheimer’s, data generally suggested they could experience slower decline with the device, particularly if they used it nearly every day for close to the recommended 60 minutes.
Based on that, Cognito’s chief executive, Christian Howell, said the company planned to seek Food and Drug Administration approval.
“The signal we found in the mild population is really incredible,” Mr. Howell said in an interview. He attributed the trial’s failure to meet its primary goal to “the lack of treatment effect” in patients with moderate Alzheimer’s, but said that for mildly impaired patients, “there is a very clear path for us to the F.D.A.”
Related Content
Advertisement